Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow‐up of MDS patients.

[1]  A. Órfão,et al.  Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet , 2021, Cytometry. Part B, Clinical cytometry.

[2]  E. Colado,et al.  ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry , 2021, Cytometry. Part B, Clinical cytometry.

[3]  U. Platzbecker,et al.  Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact , 2021, Cytometry. Part B, Clinical cytometry.

[4]  A. Porwit,et al.  Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma , 2021, European journal of haematology.

[5]  Y. Saeys,et al.  Computational flow cytometry as a diagnostic tool in suspected‐myelodysplastic syndromes , 2021, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[6]  F. Ciccarelli,et al.  ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data , 2021, eLife.

[7]  J. Jansen,et al.  Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)‐mutant myelodysplastic syndromes subtype , 2021, British journal of haematology.

[8]  T. D. de Gruijl,et al.  Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes , 2021, Haematologica.

[9]  J. Vial,et al.  Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia , 2021, Cancers.

[10]  L. Nilsson,et al.  Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome , 2021, Annals of Hematology.

[11]  C. E. Pedreira,et al.  Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study , 2020, Modern Pathology.

[12]  P. Campbell,et al.  SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS , 2020, Blood.

[13]  P. Campbell,et al.  SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). , 2020, Blood.

[14]  S. Shoaie,et al.  Integrating the "Immunome" in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Revised International Prognostic Scoring System , 2020, Definitions.

[16]  E. Solary,et al.  Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with an associated inflammatory state , 2020, Haematologica.

[17]  A. A. van de Loosdrecht,et al.  Computational analysis of flow cytometry data in hematological malignancies: future clinical practice? , 2019, Current opinion in oncology.

[18]  D. Steensma.  The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS) , 2019, Current Hematologic Malignancy Reports.

[19]  T. P. Hofer,et al.  6-Sulfo LacNAc (Slan) as a Marker for Non-classical Monocytes , 2019, Front. Immunol..

[20]  T. D. de Gruijl,et al.  Thrombomodulin-expressing monocytes are associated with low-risk features in myelodysplastic syndromes and dampen excessive immune activation , 2019, Haematologica.

[21]  L. Pleyer,et al.  Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions , 2019, Haematologica.

[22]  G. Nolan,et al.  Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation , 2019, bioRxiv.

[23]  M. Fontenay,et al.  The fraction of CD117/c‐KIT‐expressing erythroid precursors predicts ESA response in low‐risk myelodysplastic syndromes , 2019, Cytometry. Part B, Clinical cytometry.

[24]  E. Solary,et al.  Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults , 2018, HemaSphere.

[25]  E. Solary,et al.  High sensitivity of the Hematoflow™ solution for chronic myelomonocytic leukemia screening , 2018, Cytometry. Part B, Clinical cytometry.

[26]  D. Subirá,et al.  Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low‐risk myelodysplastic syndrome. Is it feasible? , 2018, Cytometry. Part B, Clinical cytometry.

[27]  J Verde,et al.  Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia , 2017, Leukemia.

[28]  E. Solary,et al.  Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. , 2017, Blood.

[29]  B. Ebert,et al.  Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions , 2017, Oncotarget.

[30]  A. Órfão,et al.  Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group , 2017, Haematologica.

[31]  V. V. D. van der Velden,et al.  Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes , 2017, Haematologica.

[32]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[33]  G. Ossenkoppele,et al.  Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System. , 2016, European journal of cancer.

[34]  G. Ossenkoppele,et al.  The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system , 2016, Leukemia.

[35]  G. Ossenkoppele,et al.  Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias. , 2016, European journal of cancer.

[36]  Ø. Bruserud,et al.  Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome , 2015, Oncoimmunology.

[37]  Piet Demeester,et al.  FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry data , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[38]  E. Solary,et al.  Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. , 2015, Blood.

[39]  P. M. van de Ven,et al.  Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes , 2015, Haematologica.

[40]  T. Haferlach,et al.  Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients , 2015, Cytometry. Part B, Clinical cytometry.

[41]  G. Ehninger,et al.  Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring , 2015, Haematologica.

[42]  M. Cazzola,et al.  Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) , 2015, Leukemia.

[43]  M. Ballesteros,et al.  Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts , 2015, Annals of Hematology.

[44]  G. Ossenkoppele,et al.  High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes , 2014, British journal of haematology.

[45]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[46]  A Orfao,et al.  Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS , 2014, Leukemia.

[47]  G. Ossenkoppele,et al.  Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. , 2014, Cytometry. Part B, Clinical cytometry.

[48]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[49]  M. Cazzola,et al.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.

[50]  A. A. van de Loosdrecht,et al.  Cutting edge: flow cytometry in myelodysplastic syndromes. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[51]  M. Béné,et al.  Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes , 2013, Leukemia.

[52]  A. Órfão,et al.  Combined flow cytometric assessment of CD45, HLA‐DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes , 2013, Cytometry. Part B, Clinical cytometry.

[53]  T. Haferlach,et al.  Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics , 2013, Haematologica.

[54]  M. Cazzola,et al.  Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group , 2012, Leukemia & lymphoma.

[55]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[56]  C. Pascutto,et al.  Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study , 2012, Haematologica.

[57]  V. V. D. van der Velden,et al.  Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS. , 2012, Leukemia research.

[58]  C. Steidl,et al.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  A. Órfão,et al.  Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group , 2012, Leukemia.

[60]  E. Estey,et al.  Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Loken,et al.  Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias , 2011, Cytometry. Part B, Clinical cytometry.

[62]  V. Viallon,et al.  p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes , 2010, Haematologica.

[63]  T. Haferlach,et al.  Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome , 2010, Cancer.

[64]  T. Fest,et al.  Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases , 2010, Haematologica.

[65]  G. Ossenkoppele,et al.  Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. , 2010, Blood.

[66]  T. Haferlach,et al.  Clinical Utility of Multiparameter Flow Cytometry in the Diagnosis of 1013 Patients with Suspected Myelodysplastic Syndrome: Correlation to Cytomorphology, Cytogenetic, and Clinical Data. , 2009 .

[67]  Wolfgang Kern,et al.  Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes , 2009, Haematologica.

[68]  D. Margaritis,et al.  Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS) , 2009, Leukemia.

[69]  M. Loken,et al.  The role of flow cytometry in myelodysplastic syndromes. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[70]  V. V. D. van der Velden,et al.  Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. , 2008, Blood.

[71]  A. Órfão,et al.  Flow cytometry in myelodysplastic syndromes: report from a working conference. , 2008, Leukemia research.

[72]  G. Mufti,et al.  CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). , 2007, Blood.

[73]  T. Haferlach,et al.  Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. , 2007, Leukemia research.

[74]  H. Tamura,et al.  Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. , 2006, Blood.

[75]  N. Young,et al.  Coincident myelodysplastic syndrome and T‐cell large granular lymphocytic disease: clinical and pathophysiological features , 2001, British journal of haematology.

[76]  K. Ennyu.  [Clinical application of flow cytometry]. , 1988, Rinsho byori. The Japanese journal of clinical pathology.